Management of haemophilia and heritable bleeding disorders in the ED
- PMID: 40579048
- DOI: 10.1136/emermed-2024-214669
Management of haemophilia and heritable bleeding disorders in the ED
Abstract
This practice review addresses the management of haemophilia and heritable bleeding disorders in the ED. These disorders are uncommonly encountered by the emergency physician, but prompt and appropriate management is critical to ensure good outcomes. This practice review describes the principles of emergency care for people with bleeding disorders, with an emphasis on a pragmatic clinical approach, and provides examples of challenging emergencies.
Keywords: Emergency Medicine; Hemophilia A; acute care; hematology; triage.
© Author(s) (or their employer(s)) 2025. No commercial re-use. See rights and permissions. Published by BMJ Group.
Conflict of interest statement
Competing interests: The following authors have received support for attendance at conferences related to haemophilia: KF from Sobi, R Gooding from Roche and from Sobi, DG from CSL Behring, Roche and Sobi, EHH from Roche and CSL Behring, WT from CSL Behring and Novo Nordisk. The following authors have received honoraria for writing a manuscript or providing a lecture: R Gooding from Sobi, R Gorman from Pfizer, DG from Sobi, DH from Sobi, CLP from Sobi, WT from Bayer, Pfizer, AstraZeneca, Takeda, Novo Nordisk, CSL Behring, Alexion, Portola, Sanofi and Sobi. The following authors have provided external consultancy: R Gooding for Sobi, CLP for Sobi, WT for Pfizer, AstraZeneca, Sanofi, Ablynx, Takeda, Novo Nordisk, Grifols, LFB Biopharmaceuticals. JM and SS provided statements indicating no competing interests. EHH is the chair of the UK Haemophilia Doctors Organisation Emergency Care Task Force: unpaid. DH is the chair of the Haemophilia Chartered Physiotherapy Association: unpaid.
Publication types
LinkOut - more resources
Full Text Sources